Expression of serine peptidase inhibitor Kunitz type 1 in differentiated thyroid cancer.
Chien-Liang LiuPo-Sheng YangMing-Nan ChienYuan-Ching ChangChi-Hsin LinShih-Ping ChengPublished in: Histochemistry and cell biology (2018)
SPINT1, also known as HAI-1, is a Kunitz-type serine protease inhibitor that inhibits multiple proteases including hepatocyte growth factor (HGF) activator and matriptase. SPINT1 has been shown to modulate HGF/MET activation in certain cancer types. In the present study, we analyzed microarray datasets and found that SPINT1 was consistently upregulated in differentiated thyroid cancer. SPINT1 protein expression was investigated using tissue microarrays and independent samples of our 143 patients. Strong SPINT1 expression was observed in 61-68% of papillary thyroid cancer and 41-50% of follicular thyroid cancer. The overexpression diminished in anaplastic thyroid cancer. The SPINT1 expression in normal thyroid tissues and benign thyroid lesions was low. Furthermore, we noted that the SPINT1 expression was associated with extrathyroidal invasion, lymphovascular invasion, lymph node metastasis, advanced TNM stage, and a higher risk of recurrence in differentiated thyroid cancer. The results were in accordance with our analysis of The Cancer Genome Atlas data. In conclusion, an overexpression of SPINT1 appears to be associated with an invasive phenotype in differentiated thyroid cancer.
Keyphrases
- papillary thyroid
- lymph node metastasis
- poor prognosis
- growth factor
- end stage renal disease
- squamous cell carcinoma
- binding protein
- cell proliferation
- long non coding rna
- newly diagnosed
- chronic kidney disease
- cell migration
- ejection fraction
- transcription factor
- machine learning
- genome wide
- patient reported outcomes
- deep learning
- high resolution
- big data
- liver injury
- atomic force microscopy
- mass spectrometry
- artificial intelligence
- single molecule
- high speed